2026 07 16 Earnings UNH Q2 Fy2026

Summary

UNH's Q2 FY2026 call matters here for one mechanism, not for the beat: Optum is voluntarily dismantling the PBM spread model. Patrick Conway states nearly "95% of clients" are expected to be on "100% pass-through arrangements by the end of 2026." This is the largest PBM in the country conceding the transparency shift ahead of regulation — first-party evidence bearing directly on drug-pricing-reform-pbm-spread-compression, and it says the compression is arriving through client demand and pre-emption, not only through a rule.

Second, an AI-productivity claim on the buyer side: ambient-listening AI is live for "70% of employed Optum Health providers" targeting "exceed 90% by year-end", and the Value Connect AI platform is credited with pharmacy cost savings of "17% for early clients." Hemsley reaffirms a "13% to 16%" long-term annual earnings growth target with technology-driven productivity as a named contributor.

Admitted risks (falsifier material): commercial medical cost trend "rising above expectations" and "modestly above 11%"; Medicare Advantage enrollment declining "approximately 1.1 million" for the full year; Stars "has continued to get more challenging in recent years, as evidenced by 2026 industry scores at the lowest level in about a decade."

⚠ Extraction note (honesty flag). The transcript host returned a condensed extract rather than the full verbatim text on fetch. Every passage below in quotation marks is verbatim from the source; the connecting text is the extractor's framing, not management's words, and must not be cited as a quote. Treat the un-quoted lines as pointers, and re-fetch the source URL before resting any conviction change on a non-quoted claim. Filed partial: true.

Transcript

(condensed extract — quoted strings are verbatim; see the extraction note above)

Stephen Hemsley (CEO): Opening remarks emphasized "continuing progress toward delivering more consistent and dependable performance." Hemsley highlighted UnitedHealthcare's Medicare improvements, Optum Health's momentum, and enterprise-wide AI deployment. He stated the company remains "focused on serving consumers and care providers in ways that are reliable, affordable, and transparent," committing to simplifying processes across care approvals, accuracy, access, and digital services. On long-term growth, Hemsley reaffirmed confidence in the "13% to 16%" annual earnings growth target, noting technology-driven productivity gains as key contributors.

Tim Noel (UnitedHealthcare): Noel reported divergence in medical cost trends: Medicare running "well above historical levels, but below our expectations" due to benefit design and care management initiatives. Commercial costs remained problematic, "rising above expectations," with trends "modestly above 11%."

Key guidance updates:

• Medicare Advantage enrollment decline: "approximately 1.1 million" for full year
• Medicare margins: expected to "finish 2026 above 3%"
• Medicaid margins: expected to remain "between -1% to -1.7%"

On prior authorization, the company committed to eliminating "30% of prior authorization volume" and "nearly two-thirds of pediatric requirements" by year-end 2026.

On Stars: "The Stars program has continued to get more challenging in recent years, as evidenced by 2026 industry scores at the lowest level in about a decade."

Patrick Conway (Optum): Conway highlighted clinical improvements, noting "approximately 10% reduction in hospitalizations" in Western and Southern regions from enhanced care transitions. Rural initiatives reached "nearly 90% of U.S. counties" with "approximately 2.5 million rural patient home visits."

On pharmacy transparency, Conway stated nearly "95% of clients" expected to be on "100% pass-through arrangements by the end of 2026." AI ambient listening technology available to "70% of employed Optum Health providers," targeting "exceed 90% by year-end." Pharmacy cost savings reached "17% for early clients" using the Value Connect AI platform.

Wayne DeVeydt (CFO): Q2 adjusted EPS: "$6.38 per share," versus "$4.08" prior year. Operating earnings grew "55% year-over-year." Operating cash flow reached "approximately $11 billion, or 1.9 times net income."

Share repurchase guidance raised to "at least $5 billion" for full year, with "$4 billion deployed" through mid-July.

Full-year 2026 adjusted EPS guidance: "$19.50 to $20.00"

Segment operating earnings guidance raised:

• UnitedHealthcare: "at least $12 billion"
• Optum Health: "at least $2.2 billion"

Medical care ratio guidance: "88.1% ± 25 basis points" for 2026.

Debt-to-capital ratio: "41.2%," with a target to reach "approximately 40% by the end of 2026."